In 2022, the stock market had its worst year since the financial crisis in 2008. The S&P 500 declined 19.4%, and many industries were rocked due to inflation, supply chain, and many other issues. But two stocks that were able to prevail and deliver positive, double-digit returns include Jazz Pharmaceuticals (NASDAQ: JAZZ) and T-Mobile US (NASDAQ: TMUS) . What's noteworthy about these two stocks is that analysts still think they'll rise even further. Let's find out a bit more about these two stocks and why they still have upside potential.
In 2022, Jazz Pharmaceuticals soundly beat the markets with a return of 25%. The stock got hot in the last quarter of the year after the company released strong quarterly results.
For the quarter ending Sept. 30, Jazz's revenue of $940.7 million was up 12% from the prior-year period, and its net loss of $0.31 per share was a big improvement from the $0.86 net loss per share it reported a year earlier. And based on the strong results, the company also slightly raised the midpoint of its guidance for the year to $3.65 billion (previously, it was $3.6 billion).
For further details see:
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher